Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer

Annals of the New York Academy of Sciences

Volumn 910, Issue , 2000, Pages 196-206

  Gupta, Rajnish A ^a   DuBois, Raymond N ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; NONHUMAN; RNA TRANSLATION; TUMOR VASCULARIZATION;

ANIMALIA;

EID: 0033913275     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06709.x     Document Type: Conference Paper

References (42)

1. 1. LANDIS, S.H., T. MURRAY, S. BOLDEN & P.A. WINGO. 1999. Cancer statistics. CA Cancer J. Clin. 49: 8-1.
2. 2. DUBOIS, R.N., S.B. ABRAMSON, L. CROFFORD, R.A GUPTA., L.S. SIMON, L.B. VAN DE PUTTE & P.E. LIPSKY. 1998. Cyclooxygenase in biology and disease. FASEB J. 12: 1063-1073.
3. 3. VANE, J.R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231: 232-235.
4. 4. KUJUBU, D.A., B.S. FLETCHER, B.C. VARNUM, R.W. LIM & H.R. HERSCHMAN. 1991. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266: 12866-12872.
5. 5. XIE, W., J. CHIPMAN, D. ROBERTSON, R. ERIKSON & D. SIMMONS. 1991. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA 88: 2692-2696.
6. 6. MASKERRER, J.L., B.S. ZWEIFEL, P.T. MANNING, S.D. HAUSER, K.M. LEAHY, W.G. SMITH, P.C. ISAKSON & K. SEIBERT. 1994. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA 91: 3228-3232.
7. 7. WILLIAMS, C.W. & R.N. DUBOIS. 1996. Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Phys. 270: G393-G400.
8. 8. KURUMBAIL, RG., A.M. STEVENS, J.K. GIERSE, J.J. MCDONALD, R.A. STEGEMAN, J.Y. PAK, D. GILDEHAUS, J.M. MIYASHIRO, T.D. PENNING, K. SEIBERT, P.C. ISAKSON & W.C. STALLINGS. 1996. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384: 644-648.
9. 9. LAINE, L., S. HARPER, T. SIMON, R. BATH, J. JOHANSON, H. SCHWARTZ, S. STERN, H. QUAN & J. BOLOGNESE. 1999. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117: 776-783.
10. 10. EMERY, P., H. ZEIDLER, T.K. KVIEN, M. GUSLANDI, R. NAUDIN, H. STEAD, K. VERBURG, M., P.C. ISAKSON, R.C. HUBBARD & G.S. GEIS. 1999. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354: 2106-2111.
11. 11. WADDELL, W.R. & R.W. LOUGHRY. 1983. Sulindac for polyposis of the colon. J. Surg. Oncol. 24: 83-87.
12. 12. SMALLEY, W. & R.N. DUBOIS. 1997. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 39: 1-20.
13. 13. KINZLER, K.W., M.C. NILBERT, B. VOGELSTEIN, T.M. BRYAN, D.B. LEVY, K.J. SMITH, A.C. PREISINGER, S.R. HAMILTON, P. HEDGE, A. MARKHAM et al. 1991. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251: 1366-1370.
14. 14. POWELL, S.M., N. ZILZ, Y. BEAZER-BARCLAY, T.M. BRYAN, S.R. HAMILTON, S.N. THIBODEAU, B. VOGELSTEIN & K.W. KINZLER. 1992. APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237.
15. 15. GIARDIELLO, P.M., S.R. HAMILTON, A.J. KRUSH, S. PIANTADOSI, L.M. HYLIND, P. CELANO, S.V. BOOKER, C.R. ROBINSON & G.J. OFFERHAUS. 1993. Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328: 1313-1316.
16. 16. STEINBACH, G., P.M. LYNCH, R. PHILLIPS, M. WALLACE, E. HAWK, G. GORDON, J. SHERMAN, N. WAKABAYASHI, B. SAUNDERS, Y. SHEN, L. GODIO, S. PATTERSON, J. ABBRUZZESE, S. JESTER, K. KING, S. ZIMMERMAN & B. LEVIN. 1999. Effect of celecoxib on colorectal polyps in patients with familial adenomatous polyposis (FAP). Am. J. Gastroenterol. 94: 2687 (Abstr. 440).
17. 17. MOSER, A.R., H.C. PITOT & W.F. DOVE. 1990. A dominant mutation that predisposes to mutiple intestinal neoplasia in the mouse. Science 247: 322-325.
18. 18. SU, L.K., K.W. KINZLER, B. VOGELSTEIN, A.C. PREISINGER, A.R. MOSER, C. LUONGO, K.A. GOULD & W.F. DOVE. 1992. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668-670.
19. 19. BOOLBOL, S.K., A.J. DANNENBERG, A. CHADBURN, C. MARTUCCI, X.J. GUO, J.T. RAMONETTI, M. ABREU-GORIS, H.L. NEWMARK, M.L. LIPKIN, J.J. DECOSSE & M.M. BERTAGNOLLI. 1996. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56: 2556-2560.
20. 20. BEAZER-BARCLAY, Y., D.B. LEVY, A.R. MOSER, W.F. DOVE, S.R. HAMILTON, B. VOGELSTEIN & K.W. KINZLER. 1996. Sulindac suppresses tumorigenesis in the min mouse. Carcinogenesis 17: 1757-1760.
21. Min mouse model by the non-steroidal anti-inflammatory drug piroxicam. Cancer Res. 56: 710-714.
22. 22. NAKATSUGI, S., M. FUKUTAKE, M. TAKAHASHI, K. FUKUDA, T. ISOI, Y. TANIGUCHI, T. SUGIMURA & K. WAKABAYASHI. 1997. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn. J. Cancer Res. 88: 1117-1120.
23. 23. REDDY, B.S., C.V. RAO, A. RIVENSON & G. KELLOFF. 1993. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493-1497.
24. 24. KAWAMORI, T., C.V. RAO, K. SEIBERT & B.S. REDDY. 1998. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:409-412.
25. 25. YOSHIMI, N., M. SHIMIZU, K. MATSUNAGA, Y. YAMADA, K. FUJII, A. HARA & H. MORI. 1999. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn. J. Cancer Res. 90: 406-412.
26. 26. FUKUTAKE, M., S. NAKATSUGI, T. ISOI, M. TAKAHASHI, T. OHTA, S. MAMIYA, Y. TANIGUCHI, H. SATO, K. FUKUDA, T. SUGIMURA & K. WAKABAYASHI. 1998. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 19: 1939-1942.
27. 27. RIGAS, B., I.S. GOLDMAX & L. LEVINE. 1993. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122: 518-523.
28. 28. BORTUZZO, C., R. HANIF, K. KASHFI, L. STAIANO-COICO, S.J. SHIFF & B. RIGAS. 1996. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim. Biophys. Acta 1300: 240-246.
29. 29. QIAO, L., V. KOZONI, G.J. TSIOULIAS, M.I. KOUTSOS, R. HANIF, S. J. SHIFF & B. RIGAS. 1995. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim. Biophys. Acta 1258: 215-223.
30. 30. WILLIAMS, C.W., C. LUONGO, A. RADHIKA, T. ZHANG, L.W. LAMPS, L. B. NANNEY, R.D. BEAUCHAMP & R.N. DUBOIS. 1996. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111: 1134-1140.
31. 31. DUBOIS, R.N., A. RADHIKA, B.S. REDDY & A.J. ENTINGH. 1996. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110: 1259-1262.
32. 32. EBERHART, C.E., R.J. COFFEY, A. RADHIKA, P.M. GIARDIELLO, S. FERRENBACH & R.N. DUBOIS. 1994. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188.
33. 33. SANO, H., Y. KAWAHITO, R.L. WILDER, A. HASHIRAMOTO, S. MUKAI, K. ASAI, S. KIMURA, H. KATO, M. KONDO & T. HLA. 1995. Expression of cyclooxygenase-1 and 2 in human colorectal cancer. Cancer Res. 55: 3785-3789.
34. 34. KARGMAN, S., G. O'NEILL, P. VICKERS, J. EVANS, J. MANCINI & S. JOTHY. 1995. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55: 2556-2559.
35. 716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell 87: 803-809.
36. 36. SHIFF, S.J. & B. RIGAS. 1997. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 113: 1992-1993.
37. 37. TSUJII, M., S. KAWANO, S. TSUJI, H. SAWAOKA, M. HORI & R.N. DUBOIS. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716.
38. 38. TSUJII, M. & R.N. DUBOIS. 1995. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 83: 493-501.
39. 39. TSUJII, M., S. KUWANO & R.N. DUBOIS. 1997. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA 94: 3336-3340.
40. 40. DUBOIS, R.N., J. SHAO, H. SHENG, M. TSUJII & R.D. BEAUCHAMP. 1996. G1 delay in intestinal epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 56: 733-737.
41. 41. SHENG, H., J. SHAO, S.C. KIRKLAND, P. ISAKSON, R. COFFEY, J. MORROW, R.D. BEAUCHAMP & R.N. DUBOIS. 1997. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99: 2254-2259.
42. 42. EMERY, P. 1996. Clinical implications of selective cyclooxygenase-2 inhibition. Scand. J. Rheumatol. Suppl. 102: 23-28.